RHYTHM

📅 Upcoming

🕒 Recent(90d)

News

• Kids shouldn’t have to organize childhood around medicine
  Fewer shots, no hour-long pharmacy runs: two families show what medicine built for real life means.
  biopharma_dive · 1mo ago
• Global Mix Inc. Recalls Niwali Tejocote Capsules and Niwali Tejocote Pieces Because of Possible Health Risk
  Global Mix Inc. of Middle Village, New York, is recalling niwali Tejocote Capsules (90 capsules, Herbal Supplement) and niwali Tejocote Pieces (90 Day Supply, Herbal Supplement) because FDA analysi…
  fda_recalls · 1mo ago
• Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
  Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with oral macrocycle drug start-up Orbis Medicines.
  fiercebiotech · 1mo ago
• Abbott garners FDA nod for its TactiFlex catheter to treat AFib
  Abbot received FDA clearance for its latest-generation catheter that allows physicians more flexibility when treating atrial fibrillation in patients.
  fiercebiotech · 1mo ago
• FDA Grants Accelerated Approval to a New Breast Cancer Treatment
  The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting ne…
  fda_press · 1mo ago
• An AI drug specialist zeroes in on rare forms of obesity
  Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…
  biopharma_dive · 1mo ago
• Superluminal secures $60M for Phase 1 of genetic obesity drug
  A Boston biotech following in the footsteps of Rhythm Pharmaceuticals and others in the MC4R obesity field has raised $60 million to test its approach in Phase 1. Superluminal Medicines secured the…
  endpoints · 1mo ago
• Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP)
  FOR IMMEDIATE RELEASE - August 27, 2026 - Davie, Florida – Ana Salazar Modela Tu Cuerpo Inc. is recalling Lipofit Extreme Fat Burner 2.0, Lot 25M12F, expiration date 09/2027, to the consumer level.…
  fda_medwatch · 1mo ago
• Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
  Vivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and CEO.
  fiercebiotech · 2mo ago
• Vitruvias vanishes amid thyroid tablets recall over potential ‘superpotency’ concerns
  Vitruvias Therapeutics has “ceased operations” after voluntarily recalling a batch recall of generic thyroid tablets due to possible superpotency that could cause a range of adverse events.
  biospace · 2mo ago